Gilteritini vs Sorafenib after transplant for FLT3-ITD AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You have AML with a FLT3-ITD mutation.
- You received a stem cell transplant and achieved full remission (no visible cancer).
- You had a positive MRD test for FLT3-ITD before transplant.
- You are between 60 and 90 days after transplant with stable blood counts and no severe graft-versus-host disease.
- You have adequate kidney and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
This trial tests a new combination of drugs (gilteritinib plus a chemo regimen called FLAI) as the first treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. The goal is to see if this combination helps destroy leukemia cells better and with acceptable side effects.
This study tests a combination of two targeted drugs, gilteritinib and momelotinib, for people whose acute myeloid leukemia (AML) has returned or has not responded to standard treatment. The drugs aim to block signals that help leukemia cells grow, potentially offering a new option for those with a FLT3 mutation.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
Hear when a new Maintenance Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.